FDA Approves Takeda’s Alunbrig as First-Line Treatment Option

Takeda says FDA approved Alunbrig (brigatinib) as a first-line treatment option for patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC), a rare and serious form of lung cancer.

• The approval expands Alunbrig’s current indication to include the first-line setting
• NOTE: April 6, Takeda’s Alunbrig Approved by EC for ALK+ NSCLC Treatment

To view the source of this information click here

To contact the reporter on this story:
Jim Silver in New York at jsilver@bloomberg.net

To contact the editor responsible for this story:
Polina Noskova at pnoskova@bloomberg.net

© 2020 Bloomberg L.P. All rights reserved. Used with ...